http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 19 Dec 2024 03:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Press+Releases/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344 http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html <p> <b>- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations</b> </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fen.donga-st.com%2FMain.da&amp;esheet=54169237&amp;newsitemid=20241219254328&amp;lan=en-US&amp;anchor=Dong-A+ST&amp;index=1&amp;md5=1a5c2560e105e85e570d06bf743b0e8d" shape="rect">Dong-A ST</a> (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, <i>IMULDOSA</i> (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. </p><p> This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, <i>IMULDOSA</i> is now fully http://www.streetinsider.com/Business+Wire/Dong-A+ST+Secures+European+Approval+for+Stelara+Biosimilar+IMULDOSA/24122937.html Thu, 19 Dec 2024 03:00:00 -0400 1709 170900 A.06822034 A.08001773 A.18254799 A.26689212 A.28837022 A.60012004 O.00042037 O.01259980 O.05105684 O.15705471 O.20026344